cells (7 ) . Increased levels of ADM have been reported in patients with myocardial infarction (8 ) , congestive heart failure (9 ), hypertension (10 ) , and various diseases such as chronic kidney disease (11, 12 ) and type 2 diabetes mellitus (T2DM) (13 ) . Moreover, in small studies ADM was also increased in patients suffering from ischemic heart disease (IHD) and/or PAD (14, 15 ) . ANP has been shown to be increased in patients with diseases like coronary atherosclerosis (16 ) , heart failure (17 ) , and acute myocardial infarction (18 ) .
In contrast to ADM and ANP, the active molecule endothelin-1 (ET-1), a 21 amino acid vasoconstrictor peptide, is reported to be produced primarily by vascular endothelial cells, with detected binding sites in blood vessels, heart, and kidney (19, 20 ) . In patients with heart failure increased plasma concentrations of the C-terminal ET-1 precursor fragment (CTproET-1) have been related to all-cause mortality and mortality due to cardiovascular causes (21, 22 ) . Moreover, CT-proET-1 was reported to be a significant predictor of death or heart failure in patients after acute myocardial infarction (23 ) .
However, there is limited conclusive information about increased concentrations of the peptides midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide (MR-proANP), or CT-proET-1 in symptomatic PAD and whether such increases are independent from the established heart failure parameter N-terminal pro-B-type natriuretic peptide (NT-proBNP) and persist when those individuals with prevalent CVD are excluded. The aim of this study was therefore to investigate the role of MRproADM, MR-proANP, and CT-proET-1 plasma concentrations in symptomatic PAD.
Materials and Methods

STUDY PARTICIPANTS AND STUDY DESIGN
The Cardiovascular Disease in Intermittent Claudication Patients (n ϭ 249) were consecutively included in the study when they presented with or had a history of IC (PAD IIa or IIb according to the criteria of Fontaine), regardless of whether they had already undergone a treatment procedure (bypass surgery or intervention). Patients were excluded from the study for any of the following reasons: presence of acute or critical limb ischemia (Fontaine III or IV), impaired kidney function with serum creatinine Ͼ133 mol/L, malignancy, previous organ transplantation, or therapy with nicotinic acid or corticosteroids.
We recruited 251 control individuals from the same geographic region matched for age and T2DM. All members of the control group had volunteered to participate in the study after the publication of an invitation in local newspapers. The same exclusion criteria were used for the patients and controls. Control individuals with symptomatic PAD were excluded, but those with a history of CVD were allowed to participate. A total of 19 of the 251 controls either had a positive cardiovascular history for angina pectoris according to the Rose questionnaire (25 ) or had documented cardiovascular events or procedures, such as myocardial infarction, aortocoronary bypass surgery, percutaneous transluminal coronary angioplasty, and/or coronary angiography or stroke.
Patients and controls did not suffer from acute illnesses or clinically detectable inflammatory processes at the time of enrollment. All participants provided written informed consent and the examination protocol was approved by the ethics committee of the participating study centers.
To minimize interobserver bias all interviews and examinations at each of the 2 clinical centers were performed by 1 medical doctor who was specially trained in vascular examinations and echocardiography.
Owing to inappropriate or missing blood samples, MR-proADM, MR-proANP, and CT-proET-1 were measured in 238 patients and 245 controls. All data and analyses described in this manuscript are based on these 483 participants.
BASELINE AND VASCULAR EXAMINATION AND OTHER
PHENOTYPIC CHARACTERIZATION
Demographic data, patient histories, and atherosclerosis risk profiles were recorded via a standardized interview. A diagnosis of T2DM was determined in the study participants if their fasting plasma glucose concentration was Ն7 mmol/L and/or they were being treated with antidiabetic drugs. Participants were considered hypertensive when the systolic blood pressure was Ն140 mmHg and/or if the diastolic blood pressure was Ն90 mmHg, and/or if they were being treated with antihypertensive drugs.
LABORATORY MEASUREMENTS
Serum and EDTA plasma were obtained after an overnight fasting period and stored in aliquots at Ϫ80°C until laboratory measurements were done. We used 3 novel commercially available fully automated immunometric immunoassays (all ThermoFisher Scientific B.R.A.H.M.S KRYPTOR) for the measurement of MRproADM, MR-proANP, and CT-proET-1 according to the manufacturer's instruction manuals. NT-proBNP and high-sensitivity cardiac troponin T (hs-cTNT, fifth generation) concentrations were measured with a commercially available assay on an E170 instrument (Modular®, Roche Diagnostics). NT-proBNP and hscTNT, as well as MR-proADM, MR-proANP, and CTproET-1, showed sufficient stability concerning longterm storage (26 -29 ) . Details of these assays such as precision data are summarized in Table 1 of the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol59/issue4.
All blood samples were analyzed in batches by personnel blinded with regard to the case control status of the study participants and with patients and controls in random order on each plate. The samples were stored for a mean of 5 years until MR-proADM, MR-proANP, and CT-proET-1 were measured. The materials of patients and controls were stored under equivalent conditions of temperature and duration.
Further details on the baseline examination, such as the ankle-brachial index (ABI) measurement, phenotypic characterization, and laboratory measurements, can be found in the online Supplemental material.
STATISTICAL METHODS
We analyzed categorical and continuous data using the 2 test, unpaired t-test, or Wilcoxon rank-sum test in case of nonnormally distributed values. We identified variables associated with PAD (or prevalent CVD in PAD patients) by logistic regression analysis applying different adjustment strategies.
A test of deviances on nested models was performed to check whether MR-proADM, MR-proANP, CT-proET-1, or NT-proBNP significantly added to various adjustment models. The discriminative abilities of MR-proADM, MR-proANP, and CT-proET-1 were tested by c-statistics and integrated discrimination improvement (IDI). IDI evaluates reclassification by comparing mean predicted probabilities of events in cases compared to controls when adding new variables All analyses were conducted in SPSS version 18.0 (IBM SPSS software) and R 2.14.1.
Results
BASELINE CHARACTERISTICS
Between 2002 and 2006, we included 249 unrelated male patients (age range, 38 -69 years) presenting with IC graded as Fontaine stage IIa or IIb. A total of 38 of these patients had T2DM. The patients and the ageand T2DM-matched controls had similar mean (SD) T2DM durations [11.7 (7.5) vs 11.5 (9.0) years]. MRproADM, MR-proANP, and CT-proET-1 were measured in 238 patients and 245 controls. Table 1 provides an overview of the characteristics of the patients and controls with MR-proADM, MRproANP, and CT-proET-1 plasma concentrations available. The patient group had a significantly higher frequency of smokers and significantly higher triglyceride, C-reactive protein (CRP), and glucose concentrations. HDL cholesterol, creatinine, and albumin concentrations were significantly lower in the patient group compared to the control group. Hypertension and prevalent CVD events were more frequent in the patient group. Table 1 shows that patients with PAD had significantly higher MR-proADM, MR-proANP, and CT-proET-1 concentrations than controls. Table 2 lists correlations between MR-proADM, MR-proANP, and CT-proET-1 and various parameters. MR-proADM and MR-proANP as well as MR-proANP and CT-proET-1 correlated moderately (r 2 ϭ 0.360 and 0.354, respectively, both P Ͻ 0.001). MR-proADM and CT-proET-1 correlated to a higher extent (r 2 ϭ 0.671, P Ͻ 0.001).
MR-proADM, MR-proANP, AND CT-proET-1 IN PATIENTS AND
CONTROLS
MULTIPLE LOGISTIC REGRESSION ANALYSIS
We investigated whether MR-proADM, MR-proANP, or CT-proET-1 concentrations are associated with PAD. Each increase of MR-proADM, MR-proANP, and CT-proET-1 by 1 SD was significantly associated with symptomatic PAD: odds ratio (OR) ϭ 1.78 (95% CI, 1.41-2.25, P Ͻ 0.001), OR ϭ 1.32 (95% CI, 1.06 -1.66, P ϭ 0.014), and OR ϭ 1.80 (95% CI, 1.43-2.28, P Ͻ 0.001), respectively (Table 3 , model 1). After additional adjustment for log CRP, serum creatinine, HDL cholesterol, and current smoking the association was still highly significant for all 3 parameters: MR-proADM (OR ϭ 1.60, P ϭ 0.002), MR-proANP (OR ϭ 1.65, P ϭ 0.002), and CTproET-1 (OR ϭ 1.67, P Ͻ 0.001), respectively (Table  3 , model 2). When additionally accounting for log NT-proBNP, MR-proADM was borderline significant (OR ϭ 1.33, P ϭ 0.08), whereas CT-proET-1 remained significantly associated (OR ϭ 1.44, P ϭ 0.021) ( Table 3 , model 3). We furthermore analyzed if estimates in each model changed when we excluded individuals with prevalent CVD. MR-proADM and CT-proET-1 did not show major differences in estimates; however, MRproANP was no longer significant (Table 3) . Pro-ADM, Pro-ANP, and Pro-Endothelin-1 in PAD Clinical Chemistry 59:4 (2013) 695
COMPARISONS OF MODELS
To evaluate whether the investigated biomarkers contributed to better discrimination between patients and controls, we applied various statistical concepts such as deviances, c-statistics, and IDI. In a first step we used a test of deviances on nested models to evaluate whether the association with PAD can be explained by all 4 parameters. The models including MRproADM, MR-proANP, CT-proET-1, or log NTproBNP showed significantly improved model fits compared to model 2, with all P Յ 0.003, (Table 4) . MR-proADM, MR-proANP, and CT-proET-1 also provided improved model fits compared to a model including age and log NT-proBNP as an established marker for functional cardiac impairment (Table 5 , all P Յ 0.003). In the extended model 3, including log NT-proBNP, only CT-proET-1 significantly improved model fit ( Table 5 ).
The c-statistics improved significantly for all models containing the 4 cardiac biomarkers (0.685 for log NT-proBNP, 0.564 for MR-proANP, 0.645 for MRproADM, and 0.633 for CT-proET-1, respectively) compared to a model including only age [c-statistic, 0.499 (0.445-0.550)]. The c-statistics for all 4 biomarkers were not significantly different from the c-statistic of the extended adjustment model 2, as can be seen from the overlapping 95% bootstrap CIs (Table 4 ). The same holds true for comparisons of the c-statistics of the model containing age and log NT-proBNP or the extended model 3 and log NT-proBNP with the c-statistics with the addition of MR-proADM, MRproANP, or CT-proET-1 (Table 5) .
However, owing to the fact that measures such as IDI are supposed to be more sensitive than the c-statistic because IDI includes the assessment of risk reclassification, we calculated the IDI for MRproADM, MR-proANP, CT-proET-1, and log NTproBNP. We observed a positive and significant IDI (P Ͻ 0.05) for all 4 markers when we compared them to the model including only age and the extended adjustment model 2 ( Table 4 ). The IDI increase was about twice as high for log NT-proBNP (absolute IDI, 0.053; relative IDI, 0.15; P Ͻ 0.0001) compared to MRproADM, MR-proANP, and CT-proET-1, respectively. Nonetheless, MR-proADM (absolute IDI, 0.02; relative ID, 0.17; P ϭ 0.002) and CT-proET-1 (absolute IDI, 0.02; relative IDI, 0.17; P ϭ 0.002) still provide improved reclassification compared to the model containing age and log NT-proBNP. However, a trend in IDI increase was observed only for CT-proET-1 (absolute IDI, 0.008; relative IDI, 0.02; P ϭ 0.068) when compared to the extended model 3 including log NTproBNP (Table 5) .
SENSITIVITY ANALYSES
We performed several sensitivity analyses: a model for MR-proADM, MR-proANP, and CT-proET-1 in which model 2 was additionally adjusted for log urine albumin/ creatinine ratio, hypertension, ejection fraction, log hscTNT, triglycerides, or hemoglobin A 1c . These analyses did not reveal substantial differences in estimates.
PREVALENT CVD
We applied multiple logistic regression analysis to test which marker (MR-proADM, MR-proANP, or CTproET-1) is associated with prevalent CVD in PAD patients. Each increase of MR-proANP by 1 SD adjusted for log CRP, serum creatinine, HDL cholesterol, and current smoking was highly significantly associated with prevalent CVD (OR, 1.80; 95% CI, 1.23-2.62; P ϭ 0.002). After further adjustment for log NT-proBNP, the P value of the association was only of borderline significance (P ϭ 0.063, Table 6 ). This result, however, has to be viewed with caution because of the high correlation between MR-proANP and log NT-proBNP (r ϭ 0.76, P Ͻ 0.001). There was a trend only for ageadjusted MR-proADM and CT-proET-1, which com- a Model 1, adjusted for age; model 2, adjusted for age, log C-reactive protein, creatinine, HDL cholesterol, and current smoking; model 3, adjusted for age, log C-reactive protein, creatinine, HDL cholesterol, current smoking, and log NT-proBNP. b The ORs for PAD status were estimated for each increment of 1 SD of MR-proADM, MR-proANP, and CT-proET-1. The SD was calculated on the basis of the values of the total group or the total group excluding those with prevalent CVDs, respectively. c The SDs for each of the biomarkers were as follows: for MR-proADM, the 1-SD increment was 0.15 nmol/L for all patients and controls and 0.13 nmol/L for all patients and controls excluding CVDs; for MR-proANP, the 1-SD increment was 48 pmol/L for all patients and controls and 35 pmol/L for all patients and controls excluding CVDs; for CT-proET-1, the 1-SD increment was 13 pmol/L for all patients and controls and 12 pmol/L for all patients and controls excluding CVDs. pletely disappeared after further adjustment for other risk factors (see Table 6 ).
Table 4. Logistic regression analysis comparing deviances, c-statistics, and IDI indices of new cardiac markers to basic risk models.
Deviance
Difference in deviance
Discussion
In this study we investigated the 3 peptides MRproADM, MR-proANP, and CT-pro-ET1 in a cohort of patients with symptomatic PAD defined by IC and an age-and diabetes-matched control group. We observed significantly higher concentrations of MRproADM, MR-proANP, and CT-pro-ET1 in PAD patients than in controls. The higher the concentrations of all 3 peptides, the higher was the risk for the presence of PAD. Moreover, MR-proADM and CT-pro-ET1 provided incremental information beyond major risk markers such as NT-proBNP. Additionally, effects for these 2 peptides persisted after we excluded data for individuals with prevalent CVDs. A recent review suggested a protective effect of ADM on CVD (30 ) . Plasma ADM concentrations reflect activation of defense mechanisms against vascular damage, besides vasodilation and natriuresis, such as antiinflammation and antioxidation, and exhibit proliferative effects on vascular endothelial cells and antiproliferative effects on vascular smooth muscle cells, supporting the role of ADM as an antiproliferative factor inhibiting the development of atherosclerosis (7 ) . Natriuretic peptides such as ANP not only play a role in volume and pressure homeostasis, but also show antiproliferative as well as antifibrotic and antiinflammatory effects (31 ) . In addition to its vasoconstricting properties, ET-1 has been reported to mediate vessel remodeling by interacting with growth factors and cytokines. Further actions of ET-1 are the promotion of vascular inflammation and excessive oxidative stress (32, 33 ) .
In several studies increased ADM, ANP, and CTproET-1 concentrations have been observed in different CVD end points (8, 9, 17, 18, (21) (22) (23) . Investigations in PAD disease are sparse, and previous studies were limited by study populations with only a small number of individuals. In a study with 35 patients with and 37 patients without PAD, ADM concentrations were negatively correlated with ABI and positively with high-sensitivity CRP (15 ) . In the CAVASIC study we also found a significant but moderate negative correlation between MR-proADM and ABI (r ϭ Ϫ0.291) and a significant positive correlation with CRP (r ϭ 0.308). In a further study, Suzuki et al. observed an increase in plasma ADM concentrations in patients with cardiovascular risk factors related to the presence of vascular complications. Furthermore, these authors reported that plasma ADM was independently associated with IHD or PAD but did not clarify whether or not an isolated PAD was associated with high ADM concentrations (14 ) . This issue was clearly addressed in the present study, in which we showed that MR-proADM and CT-proET-1 were associated with symptomatic PAD even in individuals without prevalent CVD: when patients and controls with prevalent CVD were excluded from the analyses, the association of MR-proADM and CT-proET-1 with PAD remained clearly significant. The association remained significant if data were additionally adjusted for main PAD risk factors such as age, CRP, creatinine, HDL cholesterol, hypertension, current smoking, cardiac ejection fraction, or even established markers of cardiac stress such as NT-proBNP and hs-cTNT. Therefore, it can be concluded that in Table 6 . Logistic regression analysis predicting prevalent CVD in PAD patients for MR-proADM, MR-proANP, and CT-proET-1. patients with symptomatic PAD the increase in MRproADM and CT-proET-1 might be directly linked to vascular lesions caused by PAD irrespective of cardiac dysfunction and complications, kidney function, and systemic inflammation.
The associations for MR-proANP were no longer significant after exclusion of patients and controls with prevalent CVD or adjustment for NT-proBNP. The reason why we found an overall stronger effect of MRproADM and CT-proET-1 might have been because of the production of ADM and CT-proET-1 directly in the vasculature as well as in the smooth muscle cells and more autocrine and paracrine action in this case, whereas ANP is a circulating hormone secreted mainly from the cardiac atria. This hypothesis is in line with the observation that specific receptors for ADM as well as for ET-1 are localized in the vascular endothelium in humans (7, 32 ) . Moreover, it was shown that CGRPR-1 (the calcitonin gene-related peptide receptor), a target for ADM, acts via the endothelium and not the coronary vascular smooth muscles (34 ) . Therefore, the properties of ADM and ET-1 might be more specifically related to vascular disease. In experimental and clinical studies it has been demonstrated that the infusion or increase of endogenous ADM results in a better prognosis in disorders such as heart failure or myocardial infarction and might be a promising approach for the treatment of atherosclerosis (7 ) . In PAD increasing concentrations of ADM may also rise constantly in a counteracting and compensatory manner as a reaction to preexisting vascular damage. It has also been discussed that the production of endothelins by endothelial cells is enhanced as a reaction to vascular tissue injury, a process that might be decelerated by applying selective ET-1 antagonists (32 ) . Increasing concentrations of endothelins in PAD can thus be seen as an alarming sign of a disturbed vascular function and inflammatory processes.
The presence of PAD itself is associated with an increased risk of cardiovascular or cerebrovascular events and total mortality (35 ) . The risk is already increased in patients with asymptomatic or subclinical PAD and increases considerably in PAD patients with clinical symptoms, which is important from a general health perspective because PAD is often diagnosed late (36 ) . Therefore, laboratory parameters, such as MR-proADM and CTproET-1 besides NT-proBNP, could help to improve the characterization of patients with PAD.
CLINICAL UTILITY OF THE MEASURED PARAMETERS
To better characterize PAD patients, we also investigated whether MR-proANP, MR-proADM, or CTproET-1 is associated with prevalent CVD. MRproANP and not MR-proADM or CT-proET-1 was the marker remaining significantly associated with prevalent CVD after adjustment for classical CVD risk factors. This is in line with the observation that MRproANP is a cardiac marker, whereas MR-proADM and CT-proET-1 reflect a generalized endothelial vascular dysfunction that is more evident in symptomatic PAD but not necessarily in prevalent CVD. These 3 biomarkers might be helpful in patients with T2DM who have a high risk of PAD and limb amputation as well as cardiovascular risk. MR-proADM and CTproET-1 could be considered of diagnostic value in patients in whom ABI measurement is inappropriate, such as patients with amputations as well as patients with media sclerosis. This kind of pronounced arterial stiffness is known to be highly prevalent in diabetic and/or geriatric patients and in those with longstanding hypertension. Media sclerosis results in falsely increased ABI values above 1.30. If at the same time the blood flow is decreased by arterial obstruction, the diagnosis of PAD by ABI is often masked by media sclerosis. Consequently, the ABI measurement may show normal values without pointing to media sclerosis, thereby resulting in vessels incorrectly classified as healthy. MR-proADM and CT-proET-1 should point to these patients with incorrectly normal or increased ABI who require an extended clinical examination.
The investigated biomarkers might also be especially helpful for the characterization and intensified management of risk factors in patients with diseases that limit their exercise tolerance (e.g., COPD, orthopedic problems) and who would not be able to undergo exercise tests (treadmill). Furthermore, measurements of ABI and treadmill tests are time-consuming and investigator dependent.
MEASURES OF PERFORMANCE OF PREDICTION MODELS
Various methods and measures exist for evaluating the performance of prediction models, and their pros and cons have been discussed. We provide tests of deviances on nested models, c-statistics, and IDI. IDI is reported to be more sensitive than the c-statistic because it evaluates reclassification, can be directly referred to event probabilities, and weights the improvement of sensitivity over all possible cutoffs, whereas the c-statistic weights large sensitivities to a higher extent and provides no information on the amount of change in risk. Moreover, we found that the results of the test on deviances are in line with the results of the IDI analysis for all models. Therefore, the model performance of the analyzed markers in the study at hand is described equally well by these 2 methods. All 3 applied methods indicate that NT-proBNP is the strongest marker for PAD risk determination but also show that MR-proADM and CT-proET-1 provide significant additive information beyond classical cardiac risk factors or NT-proBNP.
STRENGTHS AND LIMITATIONS
As we discussed recently (11 ) , it can be considered to be a strength of our study that we measured the markedly more stable midregional parts of the peptide precursor fragments of ADM and ANP instead of the active hormones, which have a short half life and are associated with other technical difficulties related to measurement (37, 38 ) . We also measured the CTproET-1 precursor fragment, which is much more stable than the active ET-1 (39 ) . Although the material was stored for a mean of 5 years, we do not expect that this has caused the concentration differences between cases and controls, because materials of both groups were treated identically.
Our study is limited by the fact that it is a case control study and therefore no causal conclusions can be drawn. Moreover, our study population comprised only white men. It remains to be seen whether our findings can be extrapolated to women and different ethnic groups. In addition, we have limited data on ejection fraction in both patients and controls and therefore the interpretation of this sensitivity analysis has to be treated with caution. In general, due to the high correlation of MR-proANP and NT-proBNP all regression models including both parameters have to be treated with caution as well.
Conclusions
In summary, our study of PAD patients and age-and diabetes-matched controls indicates a significant association between MR-proADM, MR-proANP, and CTpro-ET1 concentrations and PAD. The association of MR-proADM and CT-proET-1 with PAD seems to be independent from major risk factors such as NTproBNP and remains significant when excluding those with prevalent CVD.
